Epione Robotic Surgery: Quantum Surgical Cancer Treatment System
Quantum Surgical is expanding its presence in the robotic surgery market with the acquisition of NeuWave Medical, a Johnson & Johnson (J&J) business unit. The deal, finalized on , positions Quantum Surgical to offer a more comprehensive suite of tools for minimally invasive cancer treatment, particularly in the growing field of percutaneous ablation.
Epione: Robotic Precision in Tumor Ablation
At the heart of Quantum Surgical’s offering is Epione, a robotic-assisted platform designed to improve the precision and safety of percutaneous tumor ablation. This technique involves inserting needles through the skin to destroy tumors, offering a less invasive alternative to traditional surgery. While effective, percutaneous ablation has historically been limited by procedural complexities and workflow challenges. Epione aims to address these limitations by providing interventional radiologists with a standardized, image-guided approach.
The Epione system isn’t a fully autonomous robot; rather, it’s a robotic assistant. It supports physicians throughout the ablation process, enhancing their control and accuracy. The platform comprises several key components. The Epione Robot Cart
houses a robotic arm that precisely positions a needle guide at the desired location, angle, and depth. This arm is compatible with a wide range of ablation technologies – including microwave ablation (MWA), radiofrequency ablation (RFA), cryoablation, irreversible electroporation (IRE), and ethyl alcohol injection (ECT) – and accommodates various needle sizes. A dedicated camera tracks patient movement and respiration, crucial for maintaining accuracy during procedures, especially when patients are under general anesthesia.
Planning and Confirmation Software
Beyond the robotic arm, Epione incorporates sophisticated software for pre-operative planning and intra-operative confirmation. The Epione Planning Software
allows physicians to fuse pre-procedure MRI and intra-operative CT images, providing a detailed visualization of the tumor and surrounding tissues. A Smart Segmentation
tool streamlines the process of identifying the tumor’s boundaries, while the Smart Planning
module suggests optimal needle placements and patterns based on the chosen ablation technology. This aims to achieve comprehensive tumor coverage with minimal damage to healthy tissue.
Crucially, Epione also offers real-time confirmation of ablation success. The Epione Confirmation Software
allows physicians to assess tumor margin coverage immediately following the procedure, potentially reducing the need for repeat ablations. This immediate feedback is a significant advancement in the field.
Expanding into Musculoskeletal Applications
Originally focused on abdominal and lung cancers, Epione has recently received clearance for musculoskeletal (MSK) procedures. This expands the platform’s applicability to bone ablation and consolidation, offering a new approach for treating bone tumors and other MSK conditions. The device currently holds CE marking for abdomen, chest, and musculoskeletal structures, and FDA clearance for abdominal ablation.
NeuWave Acquisition: Complementary Technologies
The acquisition of NeuWave Medical is a strategic move for Quantum Surgical. NeuWave specializes in microwave ablation technology, a technique that uses heat to destroy tumors. Integrating NeuWave’s expertise with Epione’s robotic precision has the potential to further enhance the effectiveness and control of percutaneous ablation. According to reports, the acquisition will allow Quantum Surgical to leverage NeuWave’s existing portfolio and pipeline.
Microwave ablation is particularly well-suited for treating certain types of tumors due to its ability to create larger ablation zones quickly. Combining this with the robotic guidance of Epione could lead to more efficient and precise tumor destruction, potentially reducing procedure times and improving patient outcomes.
The Growing Surgical Robotics Market
This acquisition occurs within a rapidly expanding surgical robotics market. Demand for minimally invasive procedures is increasing, driven by factors such as reduced pain, shorter recovery times, and lower complication rates. Advancements in artificial intelligence and imaging technologies are further fueling this growth, enabling the development of more sophisticated and capable robotic systems.
Quantum Surgical’s Epione system is positioned to capitalize on these trends. The company has already treated over 1,400 patients worldwide and has installations in more than 15 cancer centers. With the addition of NeuWave’s technology, Quantum Surgical aims to accelerate the development of new applications and broaden its market reach, solidifying its position as a key player in the evolving landscape of interventional oncology.
Dr. Romain L’Huilier of Hospices Civils de Lyon (Lyon, France) noted that the Epione system has enabled young physicians in our department to carry out complex multi-needle procedures, previously performed only by the department’s most experienced operators.
This suggests that the platform’s ease of use and precision can help democratize access to advanced ablation techniques, potentially improving patient care across a wider range of institutions.